BRIEF published on 07/22/2026 at 18:05, 2 months 2 days ago BIOSYNEX's half-year revenue is down Revenue BIOSYNEX Pharmacy Division Diagnostic Division Debt Rescheduling
PRESS RELEASE published on 07/22/2026 at 18:00, 2 months 2 days ago BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2026 : 44,1 M€ - PERSPECTIVES Biosynex SA annonce un chiffre d'affaires de 44,1 M€ au 1er semestre 2026 avec des perspectives de rééchelonnement de dette et nouveaux marchés Chiffre D'affaires Perspectives BIOSYNEX SA 1er Semestre 2026 Rééchelonnement Dette
BRIEF published on 06/11/2026 at 07:05, 3 months 13 days ago Biosynex finalizes the sale of its molecular biology business Restructuring Transfer BIOSYNEX Molecular Biology Rapid Diagnosis
BRIEF published on 06/11/2026 at 07:05, 3 months 13 days ago Biosynex finalise la cession de son activité de biologie moléculaire Cession Restructuration BIOSYNEX Biologie Moléculaire Diagnostic Rapide
BRIEF published on 06/11/2026 at 07:05, 3 months 13 days ago Biosynex cède son activité de biologie moléculaire Cession Croissance Stratégique BIOSYNEX Biologie Moléculaire Diagnostic Rapide
BRIEF published on 06/11/2026 at 07:05, 3 months 13 days ago Biosynex sells its molecular biology business Strategic Growth Transfer BIOSYNEX Molecular Biology Rapid Diagnosis
PRESS RELEASE published on 06/11/2026 at 07:00, 3 months 13 days ago BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE Biosynex finalise la cession de son activité de biologie moléculaire avec levée des conditions suspensives. Larry Abensur commente le recentrage stratégique Stratégie Cession BIOSYNEX Biologie Moléculaire Larry Abensur
PRESS RELEASE published on 06/11/2026 at 07:00, 3 months 13 days ago BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE Biosynex annonce la réalisation de la cession de son activité de biologie moléculaire. Larry Abensur commente sur la stratégie future de la société Stratégie Cession BIOSYNEX Biologie Moléculaire Larry Abensur
BRIEF published on 05/25/2026 at 08:05, 3 months 30 days ago BIOSYNEX is considering the sale of its Molecular Biology business Pharmaceutical Industry Strategy Transfer BIOSYNEX Molecular Biology
BRIEF published on 05/25/2026 at 08:05, 3 months 30 days ago BIOSYNEX Envisage la Cession de son Activité de Biologie Moléculaire Stratégie Cession Industrie Pharmaceutique BIOSYNEX Biologie Moléculaire
Published on 09/24/2026 at 14:55, 3 hours 19 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 3 hours 44 minutes ago Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 4 hours 14 minutes ago Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026
Published on 09/24/2026 at 14:00, 4 hours 14 minutes ago Reeflex Completes $1.23 Million Goes Order on Schedule Ahead of Vancouver Investor Conference
Published on 09/24/2026 at 18:05, 9 minutes ago DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026
Published on 09/24/2026 at 18:05, 9 minutes ago EUHOMY CLOSES IFA 2026 WITH NINE HONORS ACROSS ITS ICE MAKER LINEUP
Published on 09/24/2026 at 18:00, 14 minutes ago ALTHEORA : Résultats semestriels 2026 - Cap sur la rentabilité et le désendettement
Published on 09/24/2026 at 17:50, 24 minutes ago AFYREN announces its 2026 half-year financial results
Published on 09/24/2026 at 18:00, 14 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 14 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/24/2026 at 18:00, 14 minutes ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
